UA104590C2 - Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона - Google Patents

Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона

Info

Publication number
UA104590C2
UA104590C2 UAA201100098A UAA201100098A UA104590C2 UA 104590 C2 UA104590 C2 UA 104590C2 UA A201100098 A UAA201100098 A UA A201100098A UA A201100098 A UAA201100098 A UA A201100098A UA 104590 C2 UA104590 C2 UA 104590C2
Authority
UA
Ukraine
Prior art keywords
suspension formulation
dosage form
pharmaceutical dosage
capsule
capsule pharmaceutical
Prior art date
Application number
UAA201100098A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Роман Мессершмид
Рудольф Биндер
Томас БОК
Вернер Брокс
Original Assignee
Берингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104590(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берингер Ингельхайм Интернациональ Гмбх filed Critical Берингер Ингельхайм Интернациональ Гмбх
Publication of UA104590C2 publication Critical patent/UA104590C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201100098A 2008-06-06 2009-06-04 Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона UA104590C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157748 2008-06-06
PCT/EP2009/056878 WO2009147212A1 (en) 2008-06-06 2009-06-04 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Publications (1)

Publication Number Publication Date
UA104590C2 true UA104590C2 (ru) 2014-02-25

Family

ID=40911908

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100098A UA104590C2 (ru) 2008-06-06 2009-06-04 Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона

Country Status (35)

Country Link
US (4) US20110301177A1 (enExample)
EP (1) EP2299987B1 (enExample)
JP (2) JP5661031B2 (enExample)
KR (2) KR20170020557A (enExample)
CN (2) CN102056598B (enExample)
AR (1) AR072059A1 (enExample)
AU (1) AU2009254548B2 (enExample)
BR (1) BRPI0913434B8 (enExample)
CA (1) CA2726267C (enExample)
CL (1) CL2010001279A1 (enExample)
CO (1) CO6280467A2 (enExample)
CY (1) CY1120533T1 (enExample)
DK (1) DK2299987T3 (enExample)
EA (1) EA029996B1 (enExample)
EC (1) ECSP10010660A (enExample)
ES (1) ES2669469T3 (enExample)
HR (1) HRP20180709T1 (enExample)
HU (1) HUE039187T2 (enExample)
IL (1) IL208954A (enExample)
LT (1) LT2299987T (enExample)
MA (1) MA32385B1 (enExample)
MX (2) MX359229B (enExample)
MY (1) MY158930A (enExample)
NO (1) NO2299987T3 (enExample)
NZ (1) NZ603162A (enExample)
PE (1) PE20100254A1 (enExample)
PL (1) PL2299987T3 (enExample)
PT (1) PT2299987T (enExample)
RS (1) RS57142B1 (enExample)
SI (1) SI2299987T1 (enExample)
TW (1) TW201002691A (enExample)
UA (1) UA104590C2 (enExample)
UY (1) UY31879A (enExample)
WO (1) WO2009147212A1 (enExample)
ZA (1) ZA201007636B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
NO2299987T3 (enExample) 2008-06-06 2018-07-21
WO2011151087A1 (en) * 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN106031716B (zh) * 2015-03-13 2022-04-15 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법
WO2018080795A1 (en) * 2016-10-25 2018-05-03 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
RS67241B1 (sr) 2017-10-23 2025-10-31 Boehringer Ingelheim Int Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild)
WO2019106692A1 (en) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Oral suspension of nintedanib esylate
PE20201502A1 (es) 2018-03-07 2020-12-29 Pliant Therapeutics Inc Compuestos de aminoacidos y metodos de uso
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
WO2020053665A2 (en) * 2018-09-13 2020-03-19 Ftf Pharma Private Limited Non-aqueous chemotherapeutic suspensions for oral dosage
US20210346302A1 (en) * 2018-10-15 2021-11-11 Cipla Limited Pharmaceutical Formulation
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
EP4069227A1 (en) 2019-12-04 2022-10-12 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN115361950A (zh) 2020-04-01 2022-11-18 勃林格殷格翰国际有限公司 生物标记物在治疗纤维化病症中的用途
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
JP2024539645A (ja) * 2021-10-14 2024-10-29 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤及び他の薬剤と組み合わせたその使用
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
EP4486326A1 (en) 2022-02-28 2025-01-08 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
JP2025525881A (ja) 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
SI1948180T1 (sl) 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
NO2299987T3 (enExample) 2008-06-06 2018-07-21
EP2985025B1 (en) 2008-06-06 2018-01-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
WO2010081817A1 (en) * 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
AR072059A1 (es) 2010-08-04
JP2014208712A (ja) 2014-11-06
US20140004187A1 (en) 2014-01-02
PT2299987T (pt) 2018-05-21
CA2726267A1 (en) 2009-12-10
PE20100254A1 (es) 2010-04-21
KR20110017872A (ko) 2011-02-22
BRPI0913434A2 (pt) 2015-12-01
CN105193720B (zh) 2018-07-31
IL208954A (en) 2017-11-30
NZ603162A (en) 2014-05-30
MX359229B (es) 2018-09-20
WO2009147212A1 (en) 2009-12-10
US20160022672A1 (en) 2016-01-28
CY1120533T1 (el) 2019-07-10
PL2299987T3 (pl) 2018-08-31
EP2299987B1 (en) 2018-02-21
CL2010001279A1 (es) 2011-05-13
MX2010013203A (es) 2011-02-25
TW201002691A (en) 2010-01-16
AU2009254548A1 (en) 2009-12-10
US20160324791A1 (en) 2016-11-10
BRPI0913434B1 (pt) 2020-10-13
MA32385B1 (fr) 2011-06-01
LT2299987T (lt) 2018-05-25
CN102056598A (zh) 2011-05-11
BRPI0913434B8 (pt) 2021-05-25
CN102056598B (zh) 2017-09-19
JP2011522812A (ja) 2011-08-04
HRP20180709T1 (hr) 2018-06-15
DK2299987T3 (en) 2018-05-22
AU2009254548B2 (en) 2015-10-01
ZA201007636B (en) 2011-08-31
JP5661031B2 (ja) 2015-01-28
KR20170020557A (ko) 2017-02-22
ES2669469T3 (es) 2018-05-25
CA2726267C (en) 2017-10-31
US20110301177A1 (en) 2011-12-08
EA029996B1 (ru) 2018-06-29
US9907756B2 (en) 2018-03-06
IL208954A0 (en) 2011-01-31
ECSP10010660A (es) 2011-02-28
NO2299987T3 (enExample) 2018-07-21
SI2299987T1 (en) 2018-06-29
EA201001856A1 (ru) 2011-06-30
UY31879A (es) 2010-01-29
EP2299987A1 (en) 2011-03-30
HUE039187T2 (hu) 2018-12-28
MY158930A (en) 2016-11-30
RS57142B1 (sr) 2018-07-31
CN105193720A (zh) 2015-12-30
CO6280467A2 (es) 2011-05-20
KR101725469B1 (ko) 2017-04-11
JP5905542B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
UA104590C2 (ru) Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
MX338001B (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona.
MY149731A (en) Compounds
MX2007001099A (es) Procedimiento para preparar un producto de microcapsula de alta estabilidad y metodo para uso del mismo.
PH12013501256A1 (en) Compositions and methods for modulating fxr
MY169377A (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JO2515B1 (en) Gamma crystalline form of epabradine hydrochloride, its preparation process and its pharmaceutical ingredients
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
WO2010049449A3 (en) Novel salts of sunitinib
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
TW200616952A (en) Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride
TW200700062A (en) Pharmaceutical compositions
WO2009071691A3 (de) Oxindol-derivate und ihre verwendung als medikament
TN2010000558A1 (en) Capsule pharmaceutical doage form comprising a suspension formulation of an indolinone derivative
WO2009120844A3 (en) Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
TN2010000555A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
TH115893A (th) รูปแบบขนาดยาทางเภสัชกรรมชนิดแคปซูลซึ่งประกอบรวมด้วยสูตรผสมสารแขวนลอยของอนุพันธ์อินโดลิโนน
TN2010000243A1 (en) Pharmaceutical composition
MX2010007950A (es) Formas salinas de un derivado de 6-fluoro-1,2-dihidro-2-oxo-3h-ind ol-3-ilideno, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
MX339536B (es) Procedimiento para preparar un producto de microcapsula de alta estabilidad y metodo para uso del mismo.